Literature DB >> 19465153

Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting.

Jeffrey Cloud1, Laura Noddin, Amanda Pressman, Mary Hu, Ciaran Kelly.   

Abstract

BACKGROUND & AIMS: Recent outbreaks of Clostridium difficile infection (CDI) in North America and in Europe with very high case-fatality rates have been associated with infection by North American Pulsed Field Type I (NAP-1) isolates. This study examined whether NAP-1 strains are associated with worse outcomes of CDI in a nonepidemic, nosocomial setting.
METHODS: All cases of CDI that occurred over a 13-month period at a tertiary medical center were examined for risk factors associated with increased severity of CDI and other outcomes. Stool samples from each patient were cultured for C difficile and the resulting isolates were strain-typed by pulsed-field gel electrophoresis.
RESULTS: Strain types were obtained from 236 of 272 CDI samples; the NAP-1 strain was identified in 59 (25%). In this inpatient cohort of patients with CDI, the incidence of in hospital death was 12.1% and of death caused by CDI was 4.0%. Of the patients with CDI, 22.1% met the combined outcome end point of severe CDI. In both univariate and multivariate analyses, patients infected with the NAP-1 strain did not have worse outcomes compared with those infected with non-NAP-1 strains. Infection with the NAP-1 strain was correlated with admission from outside health care facilities regardless of whether symptoms of CDI began before or after admission to the study hospital.
CONCLUSIONS: The NAP-1 strain of C difficile was found to cause 25% of cases of CDI in the hospital where the study was performed. However, compared with non-NAP-1 strains, CDI was not associated with increased severity of disease in this nonepidemic setting.

Entities:  

Mesh:

Year:  2009        PMID: 19465153     DOI: 10.1016/j.cgh.2009.05.018

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  42 in total

1.  Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Authors:  Stéphanie Sirard; Louis Valiquette; Louis-Charles Fortier
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

2.  Binary toxin and its clinical importance in Clostridium difficile infection, Belgium.

Authors:  T Pilate; J Verhaegen; M Van Ranst; V Saegeman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-08       Impact factor: 3.267

3.  Is fidaxomicin worth the cost? An economic analysis.

Authors:  Sarah M Bartsch; Craig A Umscheid; Neil Fishman; Bruce Y Lee
Journal:  Clin Infect Dis       Date:  2013-05-23       Impact factor: 9.079

4.  Clostridium difficile PCR Ribotype 018, a Successful Epidemic Genotype.

Authors:  Rossella Baldan; Alberto Trovato; Valentina Bianchini; Anna Biancardi; Paola Cichero; Maria Mazzotti; Paola Nizzero; Matteo Moro; Cristina Ossi; Paolo Scarpellini; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

5.  Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality.

Authors:  I Patel; M Wungjiranirun; T Theethira; J Villafuerte-Galvez; N Castillo; M Akbari; C D Alonso; D A Leffler; C P Kelly
Journal:  J Antimicrob Chemother       Date:  2016-11-14       Impact factor: 5.790

Review 6.  Laboratory diagnosis of bacterial gastroenteritis.

Authors:  Romney M Humphries; Andrea J Linscott
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

7.  Measuring the impact of Clostridium difficile Infection with the NAP1 strain on severity and mortality.

Authors:  Krishna Rao
Journal:  Clin Infect Dis       Date:  2014-06-30       Impact factor: 9.079

8.  Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada.

Authors:  Monika Wagner; Louis Lavoie; Mireille Goetghebeur
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

9.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Elena Deych; Carlos Gonzalez; Phillip I Tarr; David B Haslam
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

Review 10.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.